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Abstract 
 
Melatonin is functionally involved in the control of circadian rhythm and 
hormonal secretion.  In the present study, we investigated the roles of 
melatonin in the interaction of catecholamine synthesis with adrenocortical 
steroids by focusing on bone morphogenetic protein (BMP)-4 expressed in the 
adrenal medulla using rat pheochromocytoma PC12 cells.  Melatonin treatment 
significantly reduced the mRNA expression of catecholamine synthases, 
including the rate-limiting enzyme tyrosine hydroxylase (Th), 
3,4-dihydroxyphenylalanine decarboxylase and dopamine-β-hydroxylase 
expressed in PC12 cells.  In accordance with changes in the expression levels 
of enzymes, dopamine production and cAMP synthesis determined in the culture 
medium and cell lysate were also suppressed by melatonin.  The MT1 receptor, 
but not the MT2 receptor, was expressed in PC12 cells, and luzindole treatment 
reversed the inhibitory effect of melatonin on Th expression, suggesting that 
MT1 is a functional receptor for the control of catecholamine synthesis.  
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Interestingly, melatonin enhanced the inhibitory effect of BMP-4 on Th mRNA 
expression in PC12 cells.  Melatonin treatment accelerated BMP-4-induced 
phosphorylation of SMAD1/5/8 and transcription of the BMP target gene Id1.  
Of note, melatonin significantly upregulated Alk2 and Bmpr2 mRNA levels but 
suppressed inhibitory Smad6/7 expression, leading to the enhancement of 
SMAD1/5/8 signaling in PC12 cells, while BMP-4 did not affect Mt1 expression.  
Regarding the interaction with adrenocortical steroids, melatonin preferentially 
enhanced glucocorticoid-induced Th mRNA through upregulation of the 
glucocorticoid receptor and downregulation of Bmp4 expression, whereas 
melatonin repressed Th mRNA expression induced by aldosterone or androgen 
without affecting expression levels of the receptors for mineralocorticoid and 
androgen.  Collectively, the results indicate that melatonin plays a modulatory 
role in catecholamine synthesis by cooperating with BMP-4 and glucocorticoid in 
the adrenal medulla. 
Re: SBMB-D-16-00027R1 
Komatsubara, Otsuka, et al. 
 
 - 4 - 
Introduction 
 
The adrenal cortex and medullar tissues functionally interact in a 
paracrine manner through their close anatomical structures [1, 2].  Endogenous 
glucocorticoids promote catecholamine synthesis by inducing 
catecholamine-synthesizing enzymes via the cortico-medullary portal system in 
the adrenal [3].  We earlier reported the presence of a bone morphogenetic 
protein (BMP) system consisting of type-I and -II receptors in adrenomedullary 
cells [4, 5] as well as in adrenocortical cells [6-9].  TGF-β superfamily members 
including BMPs, growth and differentiation factors, and activins play important 
roles as autocrine/paracrine factors in the regulation of steroidogenesis [10-12].  
For instance, BMP-6 is involved in the maintenance of angiotensin II-induced 
aldosterone production by upregulating MAPK signaling [7-9], while the activin 
system is linked to the adrenocorticotropin-induced cAMP-protein kinase A 
(PKA) pathway in adrenocortical cells [6, 13].  Endogenous BMP-4 and its 
signaling machinery are expressed in the adrenal medulla and they play a 
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regulatory role in catecholamine synthesis induced by adrenocortical steroids [4, 
5]. 
On the other hand, melatonin plays crucial roles in the physiologically 
circadian and seasonal rhythms and in the functions of hormones and cytokines 
[14-16].  Melatonin actions are elicited via G protein-coupled MT1 and MT2 
receptors expressed in the brain and various peripheral tissues.  Melatonin 
receptors, mainly the MT1 receptor, have been detected in adrenal tissues and 
cells in mammals [17-20].  As for the effects of melatonin on adrenocortical 
hormones, it has been reported that melatonin, directly on the adrenal gland, 
inhibits glucocorticoid synthesis in response to adrenocorticotropin (ACTH) in 
various species [18, 21-23].  Melatonin exerts inhibitory effects on ACTH 
secretion in the anterior pituitary and cortisol production in the adrenal by 
different mechanisms.  We recently reported that melatonin suppresses ACTH 
secretion via BMP-4 action in corticotrope cells [24].  It was also found that, 
under the influence of ACTH, melatonin facilitates aldosterone production by 
cooperating with activin in adrenocortical cells [13].  Interestingly, melatonin 
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has been reported to suppress nocturnal blood pressure [25, 26].  In a clinical 
study, oral administration of melatonin significantly reduced blood pressure, the 
pulsatility index in the internal carotid artery, and levels of catecholamines [27], 
suggesting that melatonin may reduce contractile tone and activity of the 
cardiovascular system by regulating blood pressure and catecholamine levels. 
However, the effects of melatonin on adrenomedullary functions have 
yet to be elucidated.  Here we investigated roles of melatonin in catecholamine 
synthesis by focusing on BMP-4 expressed in the adrenal medulla and on the 
functional interaction with adrenocortical steroids using rat pheochromocytoma 
cells.  It was revealed that melatonin plays a modulatory role in catecholamine 
synthesis by cooperating with BMP-4 activity and glucocorticoid effects in the 
adrenal medulla.   
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Materials and Methods 
 
Reagents and supplies 
Dulbecco’s Modified Eagle’s Medium (DMEM), penicillin-streptomycin 
solution, and d-aldosterone, dexamethasone, dihydrotestosterone (DHT), 
3-isobutyl-1-methylxanthine (IBMX), melatonin, luzindole, fetal calf serum 
albumin and horse serum albumin were purchased from Sigma-Aldrich Co. Ltd. 
(St. Louis, MO).  Recombinant human BMP-4 was purchased from R&D 
Systems (Minneapolis, MN).  Normal rat adrenal tissues were obtained from 
male Sprague-Dawley (SD) rats (Charles River Laboratories, Wilmington, MA).  
The animal protocols were approved by Okayama University Institutional Animal 
Care and Use Committee. 
 
Cell culture 
The rat adrenal medullary cell line PC12 was obtained from RIKEN Cell Bank 
(Tsukuba, Ibaraki, Japan).  PC12 cells were maintained in DMEM 
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supplemented with 10% fetal calf serum (FCS), 10% horse serum (HS), 
penicillin, and streptomycin at 37°C in a 5% CO2 humidified atmosphere.  The 
culture medium was changed twice/week, and cultures were passaged at ~80% 
confluence.   
 
Catecholamine assays 
PC12 cells (3 x 105 viable cells/well) were precultured in 12-well plates with 
DMEM containing 10% FCS and 10% HS for 24 h.  The medium was then 
changed to DMEM containing 1% FCS and 1% HS, and the cells were treated 
with indicated concentrations of melatonin.  The culture medium was collected 
after 24-h culture, and the levels of catecholamines, including dopamine, 
noradrenaline and adrenaline, were determined by high-performance liquid 
chromatography (HPLC; BML, Inc., Saitama, Japan).  
 
Measurement of cAMP production 
To assess cellular cAMP synthesis, cells (3 x 105 viable cells/well) were 
Re: SBMB-D-16-00027R1 
Komatsubara, Otsuka, et al. 
 
 - 9 - 
precultured in 12-well plates with DMEM containing 10% FCS and 10% HS for 
24 h.  The medium was then changed to DMEM containing 1% FCS, 1% HS 
and 0.1 mM IBMX (a phoshodiesterase inhibitor) and the cells were treated with 
indicated concentrations of melatonin.  After 24-h culture, the medium and cell 
lysates solubilized with 0.1 m HCl were collected, and the extracellular and 
intracellular contents of cAMP were determined by EIA (Cyclic AMP EIA Kit, 
Cayman Co., Ann Arbor, MI) with assay sensitivity of 0.3 nM. 
 
RNA extraction, RT-PCR and quantitative real-time PCR analysis 
Cells (3 x 105 viable cells/well) were precultured in 12-well plates with DMEM 
containing 10% FCS and 10% HS for 24 h.  The medium was then replaced 
with DMEM containing 1% FCS and 1% HS, and the cells were treated with 
melatonin, luzindole, BMP-4, aldosterone, dexamethasone, DHT, or 
combinations of the reagents at the indicated concentrations.  After 24-h culture, 
the medium was removed and total cellular RNA was extracted using TRIzol® 
(Invitrogen Corp.) and quantified by measuring the absorbance of the sample at 
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260 nm.  Total RNA of adrenal tissues was also extracted using TRIzol® from 
male SD rats.  PCR primer pairs for other target genes were selected from 
different exons of the corresponding genes to discriminate PCR products that 
might arise from possible chromosome DNA contaminants as follows: MT1, 
145–165 and 357–377 (from GenBank accession #NM_008639); MT2, 214–235 
and 445–466 (NM_145712); androgen receptor (AR), 2521-2543 and 
2711-2734 (NM_013476); and glucocorticoid receptor (GR), 51-75 and 180-200 
(M14053).  Primer pairs for catecholamine synthase genes, including tyrosine 
hydroxylase (Th), 3,4-dihydroxyphenylalanine decarboxylase (Ddc) and 
dopamine-β-hydroxylase (Dbh), mineralocorticoid receptor (Mr), Id1, Bmp4, Alk2, 
Alk3, Bmpr2, Smad6, Smad7, and ribosomal protein L19 (Rpl19) were selected 
as we reported previously [4, 5, 28, 29].  The extracted RNA (1 µg) was 
subjected to an RT reaction using a First-Strand cDNA Synthesis System 
(Invitrogen Corp.) with random hexamer (2 ng/µl), reverse transcriptase (200 U) 
and deoxynucleotide triphosphate (dNTP; 0.5 mM) at 42°C for 50 min and at 
70°C for 10 min.  Aliquots of PCR products were electrophoresed on 1.5% 
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agarose gels and visualized after ethidium bromide staining.  For the 
quantification of each target mRNA level, real-time PCR was performed using 
the Light Cycler® Nano real-time PCR system (Roche Diagnostics GmbH) under 
optimized annealing conditions following the manufacturer’s protocol with the 
following profile: 40 cycles each at 95°C for 3 sec and 60°C for 30 sec.  The 
threshold cycle (Ct) values were calculated using the Light Cycler® Nano 
real-time PCR system software Ver1.0 (Roche Diagnostics GmbH).  The 
relative expression of each mRNA was calculated by the ΔCt method, in which 
ΔCt is the value obtained by subtracting the Ct value of Rpl19 mRNA from the Ct 
value of the target mRNA, and the amount of target mRNA relative to Rpl19 
mRNA was expressed as 2-(ΔCt).  The data are expressed as the ratio of target 
mRNA to Rpl19 mRNA. 
 
Western immunoblot analysis 
PC12 cells (1 x 105 viable cells/well) were pretreated with the indicated 
concentrations of melatonin in serum-free DMEM in the indicated experiments.  
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Cells were treated with melatonin or dexamethasone for 24 h.  In the indicated 
experiments, cells were stimulated by BMP-4 for 1 h after the treatment with 
melatonin.  The cells were then solubilized by a sonicator in 100 µl RIPA lysis 
buffer (Upstate Biotechnology, Lake Placid, NY) containing 1 mM Na3VO4, 1 mM 
NaF, 2% SDS, and 4% β-mercaptoethanol.  The cell lysates were subjected to 
SDS-PAGE/immunoblotting analysis using an anti-MT1 (R-18) antibody, an 
anti-MT2 (T-18) antibody, an anti-GR (M-20) antibody (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA), an antiphospho-SMAD1/5/8 antibody (Cell 
Signaling Technology, Inc., Beverly, MA), and an anti-ACTIN antibody 
(Sigma-Aldrich Co. Ltd.).  The integrated signal density of each protein band 
was analyzed by the C-DiGit® Blot Scanner System (LI-COR Biosciences, NE).  
For evaluating GR levels, ratios of the signal intensities of GR/actin were 
calculated. 
 
Statistical analysis 
All results are shown as means ± SEM of data from at least three separate 
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experiments, each performed with triplicate samples.  Differences between 
groups were analyzed for statistical significance using ANOVA with Fisher’s 
protected least significant difference (PLSD) test or unpaired t-test, when 
appropriate, to determine differences (StatView 5.0 software, Abacus Concepts, 
Inc., Berkeley, CA).  P values < 0.05 were accepted as statistically significant. 
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Results 
 
Effects of melatonin on catecholamine synthesis by rat adrenomedullar 
cells. 
Expression of the melatonin receptor Mt1 was detected in rat 
pheochromocytoma PC12 cells as well as in normal rat whole adrenal tissue and 
adrenal medullary tissue by RT-PCR (Fig. 1A), whereas Mt2 expression was not 
detected.  MT1 protein expression was also detected by Western blots in 
PC12 cells (Fig. 1B) regardless of the conditions of treatment with melatonin 
(100 nM) and dexamethasone (100 nM).  On the other hand, MT2 receptor 
expression was not detected either by PCR or Western blots (data not shown).   
Based on the results of our earlier studies [5], PC12 cells predominantly 
secrete dopamine, but the levels of adrenaline and noradrenaline are 
undetectable.  Mean dopamine levels of the control groups were 185 pg/ml and 
20.3 ng/well in the medium and in the cell lysate, respectively.  Melatonin 
suppressed dopamine secretion in the medium and intracellular dopamine 
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production in the cell lysate by PC12 cells (Fig. 1C).  The mRNA levels of 
catecholamine synthases, including Th, Ddc and Dbh, were also determined by 
quantitative real-time PCR analysis.  As shown Fig. 1D, the levels of Th, Ddc 
and Dbh mRNA were decreased by melatonin treatment (0.03 to 3 µM) in a 
concentration-dependent manner.   
Cells were treated with melatonin (100 to 1000 nM) in the presence or 
absence of the MT1/MT2 antagonist luzindole (10 to 100 nM) for 24 h.  
Treatment with luzindole alone did not affect the basal Th mRNA expression, 
indicating that the levels of endogenous melatonin synthesis are negligible (Fig. 
1E).  Treatment with luzindole reversed the inhibitory effects of melatonin on Th 
mRNA expression in a concentration-responsive manner, suggesting that the 
effects of melatonin are mediated via MT1 expressed on PC12 cells (Fig. 1E).  
In accordance with the results for dopamine concentration and its synthetic 
enzyme expression, cAMP synthesis in the medium and intracellular levels were 
also decreased by melatonin treatment (0.1 to 1 µM) (Fig. 1F). 
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Interaction of melatonin and BMP-4 in the regulation of catecholamine 
synthesis. 
Cells were cultured in the presence or absence of melatonin (100 nM) 
and BMP-4 (10 ng/ml) for 24 h, and the levels of TH, a rate-limiting enzyme of 
catecholamine synthesis, were determined by quantitative real-time PCR 
analysis.  As shown in Fig. 2A, treatments with melatonin and BMP-4 
contributed to a decrease in Th mRNA levels, and co-treatment with melatonin 
and BMP-4 enhanced the reduction of Th mRNA.  As shown in Fig. 2B, 
SMAD1/5/8 phosphorylation was readily induced by 1-h stimulation with BMP-4 
(10 ng/ml), and the BMP-4-induced phosphorylation of SMAD1/5/8 was 
enhanced by pretreatment with melatonin (100 nM).  The mRNA levels of Id1, 
one of the direct BMP target genes, were also increased by co-treatment with 
melatonin (100 nM) and BMP-4 (10 ng/ml) (Fig. 2C). 
To clarify the mechanism by which melatonin upregulated BMP-4 action, 
mRNA levels of Mt1 and receptors for BMP-4 pathways were examined by 
quantitative real-time PCR analysis.  BMP-4 (10 ng/ml) treatment had no effect 
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on Mt1 expression, while melatonin (100 nM) treatment increased the 
expression of endogenous Bmp4 mRNA for 24 h (Fig. 2D).  Moreover, mRNA 
levels of the BMP type-I receptor Alk2 and the type-II receptor Bmpr2 were 
significantly increased by melatonin (100 nM), while Alk3 expression was not 
significantly changed by melatonin (Fig. 2E).  Interestingly, mRNA levels of 
inhibitory Smad6 and Smad7 were reduced by melatonin treatment for 24 h, 
suggesting that melatonin facilitates SMAD1/5/8 activation through 
downregulating inhibitory Smad6/7 in PC12 cells (Fig. 2E). 
 
Interaction of melatonin and adrenocortical steroids in catecholamine 
biosynthesis. 
As shown in Fig. 3A, Th mRNA levels were significantly increased by 
independent treatments with aldosterone (100 nM), dexamethasone (100 nM) 
and DHT (100 nM) for 24 h.  Addition of melatonin (0.1 to 1 µM) suppressed Th 
mRNA expression induced by aldosterone and DHT.  On the other hand, 
melatonin treatment significantly enhanced Th mRNA expression induced by 
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dexamethasone in a concentration-responsive manner (Fig. 3A).   
Expression of Mr, Gr and Ar was detected in PC12 cells (Fig. 3B).  Of 
note, Gr mRNA level was significantly increased by melatonin treatment for 24 h, 
whereas melatonin had no effect on mRNA levels of Mr and Ar in PC12 cells 
(Fig. 3C).  The levels of GR protein expression were also concomitantly 
increased by treatment with melatonin (100 nM) (Fig. 3D).  In addition, Bmp4 
mRNA levels were decreased by melatonin (100 nM) treatment in the presence 
of dexamethasone (100 nM) (Fig. 3E).  These results suggested that 
upregulation of Gr as well as downregulation of Bmp4 induced by melatonin may 
have contributed to the enhancement of Th induction caused by co-treatment 
with glucocorticoid and melatonin.   
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Discussion 
 
In the present study, it was shown that melatonin contributed to the 
regulation of catecholamine synthesis in cooperation with BMP-4 activity and 
glucocorticoid effects.  As shown in Fig. 4, melatonin suppressed 
catecholamine production via the cAMP-PKA pathway, and melatonin and 
BMP-4 coordinately reduced catecholamine production.  As for the molecular 
mechanism, melatonin enhanced Bmp4 expression and BMP-4-induced 
SMAD1/5/8 signaling through upregulation of Alk2 and Bmpr2 and 
downregulation of Smad6/7 in rat adrenomedullary cells. 
Regarding the receptors for melatonin action, MT1, but not MT2, 
subtype was expressed in PC12 cells.  The expression of MT1 has been 
demonstrated in adrenal tissues and cells of rats, humans and primates [17-20, 
22], whereas the expression of MT2 was found by RT-PCR only in a study using 
rat adrenal tissue [17].  Treatment with the MT1/MT2 antagonist luzindole alone 
did not affect basal Th mRNA expression, indicating that the levels of 
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endogenous melatonin production in PC12 cells are negligible.  Given that 
luzindole significantly reversed the inhibitory effects of melatonin on Th mRNA 
expression, it is thought that the effects of melatonin are mediated via MT1 
receptors expressed on PC12 cells. 
We previously reported a regulatory role of BMP-4 in catecholamine 
synthesis by adrenomedullary cells [4, 5], in which BMP-4 enhanced 
catecholamine synthesis induced by adrenocortical steroids.  In the present 
study, it was revealed that co-treatment with melatonin and BMP-4 cooperatively 
suppressed catecholamine biosynthesis.  Alk2 and Bmpr2 expression levels 
were significantly increased by melatonin, though BMP-4 had no effect on Mt1 
expression in PC12 cells.  Upon binding of BMP ligands to specific type-I and 
type-II receptors, the receptor complexes cause phosphorylation of intracellular 
SMADs, which then translocate to the nucleus for regulating target gene 
transcription.  Of note, melatonin enhanced SMAD1/5/8 phosphorylation and 
Id1 mRNA expression induced by BMP-4, suggesting a functional interaction 
between melatonin and BMP-4.  Downregulation of Smad6/7 by melatonin is 
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also likely to be linked to the enhancement of BMP signaling.  Based on these 
findings, BMP-4 might play a physiological role in the regulation of 
catecholamine production in the adrenal medulla. 
Regarding the possible mechanisms by which melatonin directly 
suppresses catecholamine induction, it has been reported that a high 
concentration of melatonin inhibits the voltage-sensitive calcium-channel of 
PC12 cells in a melatonin receptor-independent manner without cAMP 
modulation by inhibiting neurotransmitter release [30], suggesting modulation of 
neurotransmitter release as a possible cellular mechanism for the antiepileptic 
effect of melatonin.  It has also been reported that melatonin inhibits 
nicotine-stimulated dopamine release [31].  Chronic exposure to pertussis toxin 
diminishes the inhibitory effect of melatonin on nicotine-invoked dopamine 
response, suggesting that this inhibition is partially mediated by the pertussis 
toxin-sensitive G-protein of the melatonin receptor. 
In the present study, the existence of a functional interaction between 
melatonin and glucocorticoids was also uncovered in the adrenal medulla.  
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Regarding the influence of melatonin on regulation of systemic steroids, it has 
been reported that melatonin inhibits the glucocorticoid response to ACTH in 
various animal models [18, 21-23].  Melatonin also directly antagonizes 
GR-mediated effects such as GR-induced apoptosis in thymocytes [32].  
Interestingly, GR action, in turn, activates catecholamine-induced melatonin 
production through inhibition of NF-kB translocation in the pineal gland [33].  
Based on these findings, we presumed that melatonin would inhibit 
glucocorticoid-induced catecholamine production.  However, in our study using 
PC12 cells, melatonin actually enhanced glucocorticoid-induced catecholamine 
synthesis with upregulation of GR expression and downregulation of Bmp4 
expression in the presence of a glucocorticoid, whereas melatonin suppressed 
the production of catecholamine induced by aldosterone and androgen without 
affecting Mr and Ar expression.  It is likely that melatonin exerts unique 
modulatory effects on GR activities depending on the cells or tissues expressing 
GR, though it remains to be determined whether the melatonin-induced GR 
upregulation is cell-specific or not.  Thus, the activities of catecholamines, 
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glucocorticoids and melatonin are mutually regulated at hormone-producing 
sites. 
A functional interaction between melatonin and TGF-β molecules has 
also been reported.  For instance, melatonin increases TGF-β synthesis in 
human prostate epithelial cells [34], leading to melatonin-mediated attenuation 
of cell proliferation.  Inhibition by melatonin of breast cancer cell proliferation 
with vitamin D3 is linked to activation of SMADs [35].  Melatonin also activates 
an osteogenic process by upregulating BMP-2 and -4 expression via the ERK 
and Wnt pathways [36].  We have also reported an inhibitory effect of melatonin 
on ACTH production by pituitary corticotrope cells, in which MT1 and BMP-4 
actions were mutually enhanced [24].  In the ovary, melatonin was shown to 
suppress BMP-6-induced SMAD1/5/8 signaling in granulosa cells [37].  In 
adrenocortical cells, melatonin facilitated aldosterone production induced by 
ACTH combined with activin via the cAMP-PKA pathway [13].  Further studies 
are needed to draw a conclusion regarding the impact of melatonin on the 
regulation of systemic catecholamine synthesis.  
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As for the interaction of catecholamine and glucocorticoids, it is known 
that endogenous glucocorticoids induce catecholamine biosynthesis by 
stimulating catecholamine-synthesizing enzymes though the cortico-medullary 
portal system [3].  Increased expression of phenylalanine N-methyltrasferase 
(PNMT) [3] and TH [38] and augmented catecholamine release from adrenal 
glands [39] are involved in this mechanism.  This is also related to the fetal 
programming of adult hypertension due to prenatal glucocorticoid exposure [40].  
In a clinical setting, there have been several clinical reports of patients with 
pheochromocytomas undergoing a crisis following the administration of 
corticosteroids [41].  However, in patients with adrenal disorders other than 
pheochromocytomas, plasma levels of catecholamines were not increased by 
dexamethasone [42], suggesting that a glucocorticoid-induced increase in 
catecholamines might occur only in the situation of pheochromocytoma as a 
non-physiological phenomenon.  Taken together, the results indicate that 
melatonin has inhibitory effects on ACTH-glucocorticoid secretion from the 
standpoint of systemic hormone regulation, whereas in the adrenal medulla, 
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melatonin enhanced the stimulatory effects of glucocorticoids on catecholamine 
synthesis, suggesting that melatonin is likely to play a regulatory role in the 
cortico-medullary portal system. 
Collectively, the results showed that melatonin action reduced 
catecholamine production via the cAMP pathway and decreased catecholamine 
production in BMP-4-treated cells via the SMAD1/5/8 pathway (Fig. 4).  In this 
mechanism, upregulation of Bmp4, Alk2 and Bmpr2 and downregulation of 
inhibitory Smad6/7 were functionally linked to the enhancement of 
BMP-4-induced SMAD1/5/8 signaling in adrenal medullary cells.  Melatonin 
also upregulated GR expression in PC12 cells, leading to the amplification of 
glucocorticoid-induced Th mRNA levels.  From a clinical standpoint, this action 
of melatonin and the functional interaction of melatonin with glucocorticoids 
could be involved in the regulation of nocturnal blood pressure [26]. 
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Figure Legends: 
Fig. 1. Expression of melatonin receptor in the rat adrenal medulla and 
effects of melatonin on catecholamine synthesis by PC12 cells.  A) Total 
cellular RNAs were extracted from PC12 cells, rat whole adrenal tissues, and 
adrenomedullary tissues.  Expression of Mt1 was detected by RT-PCR analysis.  
Aliquots of PCR products were electrophoresed and visualized by ethidium 
bromide staining.  MM indicates molecular weight marker.  B) PC12 cells were 
treated with 100 nM of melatonin or dexamethasone for 24 h.   The cell lysates 
were then subjected to SDS-PAGE/immunoblotting analysis using anti-MT1 and 
anti-ACTIN antibodies.  C) PC12 cells were cultured in DMEM containing 1% 
FCS and 1% HS, and then the cells (3 × 105 cells/well) were treated with the 
indicated concentrations of melatonin.  The culture medium and cell lysates 
were collected after 24-h culture, and dopamine levels were determined by 
HPLC and expressed as fold changes standardized by each control level.  D) 
Total cellular RNAs were extracted after 24-h culture, and mRNA levels of Th, 
Ddc, Dbh, and Rpl19 were analyzed by quantitative PCR.  The expression 
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levels of target mRNA were standardized by Rpl19 level in each sample, and 
then levels of mRNA of target genes were expressed as fold changes.  E) Cells 
(3 × 105 cells/well) cultured in DMEM containing 1% FCS and 1% HS were 
treated with the indicated concentrations of melatonin and luzindole.  Total 
cellular RNAs were extracted after 24-h culture, and mRNA levels of Th and 
Rpl19 were analyzed by quantitative PCR.  The expression levels of Th mRNA 
were standardized by Rpl19 level in each sample, and then levels of Th mRNA 
were expressed as fold changes.  F) Cells (3 × 105 cells/well) were cultured in 
DMEM containing 1% FCS and 1% HS with the indicated concentrations of 
melatonin in the presence of IBMX (0.1 mM) for 24 h.  The culture medium and 
cell lysates were collected, and the cAMP levels were determined by an enzyme 
immunoassay after acetylation and expressed as fold changes standardized by 
each control level.  Results are shown as means ± SEM.  The results were 
analyzed by ANOVA (C, D and F) or unpaired t-test (E).  Values with different 
superscript letters are significantly different at P < 0.05.  *, P < 0.05 and **, P < 
0.01 vs. control group. 
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Fig. 2. Functional interaction of melatonin activity and BMP-4 signaling in 
the regulation of catecholamine synthesis.  A) PC12 cells (3 × 105 
cells/well) cultured in DMEM containing 1% FCS and 1% HS were treated with 
the indicated concentrations of melatonin and BMP-4.  Total cellular RNAs 
were extracted after 24-h culture, and mRNA levels of Th and Rpl19 were 
analyzed by quantitative PCR. The expression levels of Th mRNA were 
standardized by Rpl19 level in each sample, and then levels of Th mRNA were 
expressed as fold changes.  B) After preculture in serum-free conditions with 
melatonin, cells (1 × 105 cells/well) were stimulated with BMP-4 for 1 h.  The 
cell lysates were then subjected to SDS-PAGE/immunoblotting analysis using 
anti-pSMAD1/5/8 and anti-ACTIN antibodies.  C) Cells (3 × 105 cells/well) 
cultured in DMEM containing 1% FCS and 1% HS were treated with the 
indicated concentrations of melatonin and BMP-4 for 8 h.  Total cellular RNAs 
were extracted and mRNA levels of Id1 and Rpl19 were analyzed by quantitative 
PCR.  The expression levels of Id1 mRNA were standardized by Rpl19 level in 
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each sample and then expressed as fold changes.  D) Total cellular RNA was 
extracted from PC12 cells treated with BMP-4 or melatonin in DMEM containing 
1% FCS and 1% HS for 24 h, and mRNA levels of Mt1 or Bmp4 and Rpl19 were 
determined by quantitative PCR.  The expression levels of target mRNA were 
standardized by Rpl19 level in each sample, and then levels of mRNA of target 
gene were expressed as fold changes.  E) Total cellular RNA was extracted 
from PC12 cells treated with the indicated concentrations of melatonin in DMEM 
containing 1% FCS and 1% HS for 24 h, and mRNA levels of Alk2, Alk3, Bmpr2, 
Smad6 and Smad7 were determined by quantitative PCR.  The expression 
levels of target mRNA were standardized by Rpl19 level in each sample, and 
then levels of mRNA of target genes were expressed as fold changes.  Results 
are shown as means ± SEM.  The results were analyzed by ANOVA (A, C) or 
unpaired t-test (D, E).  Values with different superscript letters are significantly 
different at P < 0.05.  *, P < 0.05 and **, P < 0.01 vs. control group. 
 
Fig. 3. Effects of melatonin on catecholamine biosynthesis induced by 
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adrenocortical steroids.  A, C, E) Cells (3 × 105 cells/well) were treated with 
the indicated concentrations of melatonin and/or adrenal steroids including 
aldosterone, dexamethasone and DHT in DMEM containing 1% FCS and 1% 
HS for 24 h.  Total cellular RNAs were extracted after 24-h culture, and mRNA 
levels of Th, Mr, Gr, Ar, Bmp4 and Rpl19 were analyzed by quantitative PCR.  
The expression levels of target mRNA were standardized by the level of Rpl19 in 
each sample, and then levels of mRNA of target genes were expressed as fold 
changes.  B) Total cellular RNAs were extracted from PC12 cells, and the 
expression of mRNAs encoding Mr, Gr and Ar was detected by RT-PCR 
analysis.  Aliquots of PCR products were electrophoresed and visualized by 
ethidium bromide staining.  MM indicates molecular weight marker.  D) Cells 
(1 x 105 cells/well) were treated with an indicated concentration of melatonin for 
24 h in serum-free conditions. The cell lysates were then subjected to 
SDS-PAGE/immunoblotting analysis using anti-GR and anti-ACTIN antibodies.  
The integrated signal density of each protein band was digitally analyzed, and 
the ratios of signal intensities of GR/ACTIN were calculated.  Results are 
Re: SBMB-D-16-00027R1 
Komatsubara, Otsuka, et al. 
 
 - 37 - 
shown as means ± SEM.  The results were analyzed by ANOVA (A) or 
unpaired t-test (C-E). Values with different superscript letters are significantly 
different at P < 0.05.  *, P < 0.05 and **, P < 0.01 vs. control group. 
   
Fig. 4.  Possible mechanism by which melatonin and BMP-4 regulate 
catecholamine production under the influence of adrenocortical steroids.  
Melatonin suppresses catecholamine production by inhibiting the cAMP-PKA 
pathway in cooperation with BMP-4, in which melatonin enhances BMP-4 
expression and SMAD1/5/8 signaling through upregulation of Alk2 and Bmpr2 
and downregulation of Smad6/7.  Among the adrenocortical steroids, melatonin 
preferentially facilitates the induction of catecholamine output in the presence of 
glucocorticoids through upregulating GR expression.  Melatonin may be 
involved in the functional modulation of cortico-medullary interaction in the 
adrenal. 
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